Mouse Anti-RNase L Monoclonal Antibody, Unconjugated, Clone 2E9 from Novus Biologicals
CORNING VOLUME ADAPTER FOR 96 WELL PLATES from Sigma-Aldrich
Microseal 384 Plate Positioner from Bio-Rad
...ped to significantly increase the shelf life of di...ncreased at room temperature storage conditions in...ected to 0.2 micron filtration, and contains no me...ntly high levels of activity for both the enzyme a...
Biology Products:(Date:11/24/2009)... York investment bank KTA Capital,s client Neuren ... mil convertible note private placement with a U.S...s arranged by KTA Capital as Neuren,s exclusive pl... New York (PRWEB) November 23, 2009 -- The inde...("KTA Capital") has announced that its c...
(Date:11/24/2009)... Sigma-Aldrich Corporati...AQ OMX conference on Tuesday, December 1st at 1:45...ies may listen via live audio broadcast over the I... a a ldrich.com/ . Users can click the "Webcas...-Aldrich: Sigma-Aldrich is a leading Life Scienc...
(Date:11/24/2009)..., Nov. 24 NeurogesX, Inc...cused on developing and commercializing novel pain...y DiTonno, President and Chief Executive Officer, ...affray Health Care Conference, to be held December...k, New York. ,, Mr. DiTonno and Stephen Ghigli...
(Date:11/24/2009)...y endpoint has been met for patients with advanced... QUEBEC CITY, Nov. 24 /PRNewswire-FirstCall/ - AEt... "Company"), a global biopharmaceutical company fo...ounced positive efficacy data from a Phase 2 study...ZS-108 (formerly AN-152), in patients with advance...
Breaking Biology Technology:KTA Capital Arranges an AU$6.7 Million Private Placement by Neuren Pharmaceuticals 2NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4